Glutathione modulation in cancer treatment: will it work?
Glutathione (GSH) assumes a pivotal role in numerous cellular functions including bioreductive reactions, maintenance of enzyme activity, amino acid transport, protection from harmful oxidative species, and detoxification of xenobiotics. The importance of GSH in modifying the cellular response to several anti-cancer treatment modalities has become better appreciated with the introduction of agents which can either decrease or elevate GSH levels in cells and tissues. In general, GSH depletion has been demonstrated to further enhance the cytotoxicity of several chemotherapy drugs and nitroimidazole hypoxic cell radiosensitizers. Conversely, GSH elevation affords varying degrees of protection. Whether or not GSH modulating agents will be useful as an adjuvant to selected cancer treatment modalities will depend on whether differential levels of GSH can be achieved in tumor versus normal tissues. Accurate GSH measurements in tumor and normal tissues will be required to adequately use and interpret the results of clinical studies where GSH modulating agents are employed. Precise tumor GSH measurements pose a considerable challenge due to the complicated cellular makeup of tumors.
Mitchell
J B
JB
Radiation Oncology Branch, National Cancer Institute, Bethesda, MD 20892.
Cook
J A
JA
DeGraff
W
W
Glatstein
E
E
Russo
A
A
D000970:Antineoplastic Agents / Q000627:therapeutic use*; D019328:Buthionine Sulfoximine; D002460:Cell Line; D005978:Glutathione / Q000502:physiology*; D006801:Humans; D008717:Methionine Sulfoximine / Q000031:analogs & derivatives / Q000494:pharmacology; D009369:Neoplasms / Q000503:physiopathology / Q000628:therapy*; D011838:Radiation-Sensitizing Agents
D000970:Antineoplastic Agents; D011838:Radiation-Sensitizing Agents; D008717:Methionine Sulfoximine; D019328:Buthionine Sulfoximine; D005978:Glutathione